Systemic treatment of advanced prostate cancer

作者: Alexander Kretschmer , Tilman Todenhöfer

DOI: 10.1007/S00120-020-01381-9

关键词:

摘要: In recent years there have been substantial changes in the therapeutic landscape for systemic treatment of advanced prostate cancer (PCa), which resulted a multitude novel options different stages disease. current narrative review currently available metastatic hormone-sensitive PCa as well nonmetastatic castration-resistant are presented. addition, sequence and targeted stage highlighted.

参考文章(53)
Ian F Tannock, Karim Fizazi, Sergey Ivanov, Camilla Thellenberg Karlsson, Aude Fléchon, Iwona Skoneczna, Francisco Orlandi, Gwenaelle Gravis, Vsevolod Matveev, Sevil Bavbek, Thierry Gil, Luciano Viana, Osvaldo Arén, Oleg Karyakin, Tony Elliott, Alison Birtle, Emmanuelle Magherini, Laurence Hatteville, Daniel Petrylak, Bertrand Tombal, Mark Rosenthal, Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial Lancet Oncology. ,vol. 14, pp. 760- 768 ,(2013) , 10.1016/S1470-2045(13)70184-0
Arun A. Azad, Bernhard J. Eigl, R. Nevin Murray, Christian Kollmannsberger, Kim N. Chi, Efficacy of Enzalutamide Following Abiraterone Acetate in Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer Patients European Urology. ,vol. 67, pp. 23- 29 ,(2015) , 10.1016/J.EURURO.2014.06.045
Klaus Brasso, Frederik B. Thomsen, Andres J. Schrader, Sebastian C. Schmid, David Lorente, Margitta Retz, Axel S. Merseburger, Christoph A. von Klot, Martin Boegemann, Johann de Bono, Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis European Urology. ,vol. 68, pp. 317- 324 ,(2015) , 10.1016/J.EURURO.2014.07.028
Michael T Schweizer, Xian C Zhou, Hao Wang, Sunakshi Bassi, Michael A Carducci, Mario A Eisenberger, Emmanuel S Antonarakis, None, The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer European Urology. ,vol. 66, pp. 646- 652 ,(2014) , 10.1016/J.EURURO.2014.01.018
Charles J Ryan, Matthew R Smith, Johann S De Bono, Arturo Molina, Christopher J Logothetis, Paul De Souza, Karim Fizazi, Paul Mainwaring, Josep M Piulats, Siobhan Ng, Joan Carles, Peter FA Mulders, Ethan Basch, Eric J Small, Fred Saad, Dirk Schrijvers, Hendrik Van Poppel, Som D Mukherjee, Henrik Suttmann, Winald R Gerritsen, Thomas W Flaig, Daniel J George, Evan Y Yu, Eleni Efstathiou, Allan Pantuck, Eric Winquist, Celestia S Higano, Mary-Ellen Taplin, Youn Park, Thian Kheoh, Thomas Griffin, Howard I Scher, Dana E Rathkopf, None, Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy The New England Journal of Medicine. ,vol. 368, pp. 138- 148 ,(2013) , 10.1056/NEJMOA1209096
C. Parker, S. Nilsson, D. Heinrich, S.I. Helle, J.M. O'Sullivan, S.D. Fosså, A. Chodacki, P. Wiechno, J. Logue, M. Seke, A. Widmark, D.C. Johannessen, P. Hoskin, D. Bottomley, N.D. James, A. Solberg, I. Syndikus, J. Kliment, S. Wedel, S. Boehmer, M. Dall'Oglio, L. Franzén, R. Coleman, N.J. Vogelzang, C.G. O'Bryan-Tear, K. Staudacher, J. Garcia-Vargas, M. Shan, Ø.S. Bruland, O. Sartor, Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer The New England Journal of Medicine. ,vol. 369, pp. 213- 223 ,(2013) , 10.1056/NEJMOA1213755
Gwenaelle Gravis, Karim Fizazi, Florence Joly, Stéphane Oudard, Franck Priou, Benjamin Esterni, Igor Latorzeff, Remy Delva, Ivan Krakowski, Brigitte Laguerre, Fréderic Rolland, Christine Théodore, Gael Deplanque, Jean Marc Ferrero, Damien Pouessel, Loïc Mourey, Philippe Beuzeboc, Sylvie Zanetta, Muriel Habibian, Jean François Berdah, Jerome Dauba, Marjorie Baciuchka, Christian Platini, Claude Linassier, Jean Luc Labourey, Jean Pascal Machiels, Claude El Kouri, Alain Ravaud, Etienne Suc, Jean Christophe Eymard, Ali Hasbini, Guilhem Bousquet, Michel Soulie, Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial Lancet Oncology. ,vol. 14, pp. 149- 158 ,(2013) , 10.1016/S1470-2045(12)70560-0
Christopher J. Sweeney, Yu-Hui Chen, Michael Carducci, Glenn Liu, David F. Jarrard, Mario Eisenberger, Yu-Ning Wong, Noah Hahn, Manish Kohli, Matthew M. Cooney, Robert Dreicer, Nicholas J. Vogelzang, Joel Picus, Daniel Shevrin, Maha Hussain, Jorge A. Garcia, Robert S. DiPaola, Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer The New England Journal of Medicine. ,vol. 373, pp. 737- 746 ,(2015) , 10.1056/NEJMOA1503747
Arun A. Azad, Raya Leibowitz-Amit, Bernhard J. Eigl, Renee Lester, J. Connor Wells, R. Nevin Murray, Christian Kollmannsberger, Daniel Y.C. Heng, Anthony M. Joshua, Kim N. Chi, A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer The Prostate. ,vol. 74, pp. 1544- 1550 ,(2014) , 10.1002/PROS.22872